ClinicalTrials.gg
CompletedNCT02486406ZIRCONUpdated Oct 5, 2021Results posted

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

A Phase 2/3 interventional study of Ombitasvir/paritaprevir/ritonavir and Dasabuvir in Chronic Hepatitis C Infection, sponsored by AbbVie. Completed at 21 sites in 5 countries. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-10-05.

Sponsored by AbbVie · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
64
Allocation
Non-randomized
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing Ombitasvir/Paritaprevir/Ritonavir in Hepatitis C — none open to participants now, none under way, none of them phase 3. Ombitasvir/Paritaprevir/Ritonavir · Hepatitis C.

Enrollment
6th of 12
64 · median 62
Started
2015
with 3 others
Phase 2/3
Only one
of the 12
Registered
8th of 12
by date
Lead sponsor
11 of 12
AbbVie

Among the 12 studies testing Ombitasvir/Paritaprevir/Ritonavir in Hepatitis C, this one is the 6th largest by enrollment, is one of 4 that started in 2015, is the only one in phase 2/3, and was the 8th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 12 studies testing Ombitasvir/Paritaprevir/Ritonavir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About Ombitasvir/Paritaprevir/Ritonavir

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 3 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing Ombitasvir/Paritaprevir/Ritonavir in Hepatitis C as a file.
02

Study summary

This was a Phase 2/3, open-label, multicenter study to evaluate the pharmacokinetics (PK), efficacy, and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/RTV) with or without dasabuvir (DSV) and with or without ribavirin (RBV) in Hepatitis C virus (HCV) genotype 1 or 4 (GT1 or GT4)-infected pediatric participants of ≥ 3 to 17 years of age.

Read the detailed description

The study population for Part 1, the PK study, included GT1-infected participants who were noncirrhotic and treatment-naïve (TN). Part 2, the safety and efficacy study, included GT1 or GT4-infected participants who were TN or interferon ([IFN] or Pegylated-interferon alfa-2a or 2b [pegIFN] with or without RBV) treatment-experienced (TE) without cirrhosis or with compensated cirrhosis. In Part 1 and Part 2, the treatment regimen and duration were dependent on HCV GT, GT1 subtype, and cirrhosis status.

03

Conditions studied

  • Chronic Hepatitis C Infection

Browse trials for

Keywords

  • Hepatitis C Virus
  • Hepatitis C Genotype 1
  • Hepatitis C Genotype 4
  • Pediatric
04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Positive anti- virus antibody (HCV Ab) and HCV ribonucleic acid (RNA) ≥ 1000 IU/mL at the time of screening
  2. HCV genotype 1 for enrollment into Part 1 of the study and genotype 1 or 4 for enrollment into Part 2
  3. Parent or legal guardian with the willingness and ability to provide written and participant willing and able to give assent, as appropriate for age and country

Exclusion criteria

Exclusion Criteria:

  1. Female participant who is pregnant, breastfeeding or is considering becoming pregnant
  2. Use of known strong inducers and inhibitors (e.g., gemfibrozil) of cytochrome P450 2C8 (CYP2C8) in participants receiving dasabuvir, or strong or moderate inducers of , within 2 weeks or 10 half-lives, whichever is longer, of the respective medication/supplement prior to study drug administration.
  3. Positive test result for surface antigen (HbsAg) or anti- antibody (HIV Ab) test
  4. Current enrollment in another interventional clinical study, previous enrollment in this study, prior or current use of any or commercially available anti- agents other than interferons or ribavirin or receipt of any investigational product within 6 weeks prior to study drug administration
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Adult tablet, 12-17 yr, Part 1

    Participants with HCV GT1b without cirrhosis received the adult 3-DAA (OBV/PTV/RTV and DSV) regimen: two 12.5 mg ombitasvir /75 mg paritaprevir /50 mg ritonavir tablets taken orally every morning (QD) and one dasabuvir 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis received 12-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label.

    Drug: Ombitasvir/paritaprevir/ritonavir · Drug: Dasabuvir · Drug: Ribavirin

  • Experimental
    Adult tablet, 12-17 yr, Part 2

    Participants with HCV GT1b received the adult 3-DAA (OBV/PTV/RTV and DSV) regimen: two 12.5 mg ombitasvir /75mg paritaprevir /50 mg ritonavir tablets taken orally every morning (QD) and one dasabuvir 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis received 12-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label. Participants with HCV GT1a with compensated cirrhosis received 24-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label. Participants with HCV GT4 received 12-week treatment with the OBV/PTV/RTV formulation and ribavirin 200 mg tablets were administered orally per local label.

    Drug: Ombitasvir/paritaprevir/ritonavir · Drug: Dasabuvir · Drug: Ribavirin

  • Experimental
    Mini tablet, 9-11 yr, Part 1

    Participants with HCV GT1b without cirrhosis were to receive the mini-tablet 3-DAA (OBV, PTV, RTV, and DSV) regimen for 12 weeks: ombitasvir 0.3 mg, paritaprevir 1.0 mg, and ritonavir 1.0 mg mini-tablets administered orally QD based on body weight and dasabuvir taken orally BID as 3.08 mg mini-tablets based on body weight. Participants with HCV GT1a without cirrhosis received 12-week treatment with the mini-tablet 3-DAA regimen and ribavirin was provided as a 40 mg/mL oral solution and administered per local label.

    Drug: Ombitasvir mini tablet · Drug: Paritaprevir mini tablet · Drug: Ritonavir mini tablet · Drug: Dasabuvir mini tablet · Drug: Ribavirin solution

  • Experimental
    Mini tablet, 3-8 yr, Part 1

    Participants with HCV GT1b without cirrhosis were to receive the mini-tablet 3-DAA (OBV, PTV, RTV, and DSV) regimen for 12 weeks: ombitasvir 0.3 mg, paritaprevir 1.0 mg, and ritonavir 1.0 mg mini-tablets administered orally QD based on body weight and dasabuvir taken orally BID as 3.08 mg mini-tablets based on body weight. Participants with HCV GT1a without cirrhosis received 12-week treatment with the mini-tablet 3-DAA regimen and ribavirin was provided as a 40 mg/mL oral solution and administered per local label.

    Drug: Ombitasvir mini tablet · Drug: Paritaprevir mini tablet · Drug: Ritonavir mini tablet · Drug: Dasabuvir mini tablet · Drug: Ribavirin solution

Interventions

  • DrugOmbitasvir/paritaprevir/ritonavir

    Drug page: Ombitasvir/Paritaprevir/Ritonavir

    Film-coated tablet for oral use

    Also known as: Ombitasvir also known as ABT-267, Paritaprevir also known as ABT-450, Ombitsvir/paritaprevir/ritonavir also known as Viekirax

  • Film-coated tablet for oral use

    Also known as: Exviera, ABT-333

  • Film-coated tablet for oral use

  • Film-coated tablet for oral use

    Also known as: ABT-267

  • Film-coated tablet for oral use

    Also known as: ABT-450

  • DrugRitonavir mini tablet

    Film-coated tablet for oral use

  • DrugDasabuvir mini tablet

    Film-coated tablet for oral use

    Also known as: Exviera, ABT-333

  • Oral solution

06

What researchers measure

Primary outcomes

  1. Part 1: Maximum Plasma Concentration (Cmax) of Ombitasvir (OBV)

    Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.

    Time frame: At Week 2

  2. Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Ombitasvir (OBV)

    AUC is a measure of how long and how much drug is present in the body after dosing. The amount of ombitasvir present was measured up to 24 hours after dosing.

    Time frame: At Week 2

  3. Part 1: Lowest Plasma Concentration (Ctrough) of Ombitasvir (OBV)

    Minimum plasma concentration (Ctrough; measured in ng/mL) was directly determined from the concentration-time data.

    Time frame: At Weeks 2 and 8

  4. Part 1: Maximum Plasma Concentration (Cmax) of Paritaprevir (PTV)

    Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.

    Time frame: At Week 2

  5. Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Paritaprevir (PTV)

    AUC is a measure of how long and how much drug is present in the body after dosing. The amount of paritaprevir present was measured up to 24 hours after dosing.

    Time frame: At Week 2

  6. Part 1: Lowest Plasma Concentration (Ctrough) of Paritaprevir (PTV)

    Minimum plasma concentration (Ctrough; measured in ng/mL) was directly determined from the concentration-time data.

    Time frame: At Weeks 2 and 8

  7. Part 1: Maximum Plasma Concentration (Cmax) of Dasabuvir (DSV)

    Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.

    Time frame: At Week 2

  8. Part 1: Concentration of Drug in Blood Plasma Against Time [Area Under the Curve (AUC)] of Dasabuvir (DSV)

    AUC is a measure of how long and how much drug is present in the body after dosing. The amount of dasabuvir present was measured up to 12 hours after dosing. For two subjects in the 15-29 kg group, the 24 h concentration was used as the 12 h concentration due to the significant sampling time deviation. For one subject in the 30-44 kg group, the 24 h concentration was used as the 12 h concentration due to the significant sampling time deviation.

    Time frame: At Week 2

  9. Part 1: Lowest Plasma Concentration (Ctrough) of Dasabuvir (DSV)

    Minimum plasma concentration (Ctrough; measured in ng/mL) was directly determined from the concentration-time data.

    Time frame: At Weeks 2 and 8

  10. Part 1: Maximum Plasma Concentration (Cmax) of Ritonavir (RTV)

    Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.

    Time frame: At Week 2

  11. Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Ritonavir (RTV)

    AUC is a measure of how long and how much drug is present in the body after dosing. The amount of ritonavir present was measured up to 24 hours after dosing.

    Time frame: At Week 2

  12. Part 1: Lowest Plasma Concentration (Ctrough) of Ritonavir (RTV)

    Minimum plasma concentration (Ctrough; measured in ng/mL) was directly determined from the concentration-time data.

    Time frame: At Weeks 2 and 8

  13. Parts 1 and 2: Percentage of Participants With Sustained Virologic Response 12 Weeks After the Last Actual Dose of Study Drug (SVR12)

    SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) \< lower limit of quantification (LLOQ) 12 weeks after the last actual dose of study drug.

    Time frame: 12 weeks after last dose of study drug (Week 24 or 36 depending on treatment duration)

Secondary outcomes

  1. Parts 1 and 2: Percentage of Participants With Sustained Virologic Response 12 Weeks After the Last Actual Dose of Study Drug (SVR12) Summarized by Formulation, Age and Weight Group, and Across All Subjects on the Adult Formulations

    SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) \< lower limit of quantification (LLOQ) 12 weeks after the last actual dose of study drug.

    Time frame: 12 weeks after last dose of study drug (Week 24 or 36 depending on treatment duration)

  2. Parts 1 & 2: Percentage of Participants With Sustained Virologic Response 24 Weeks After the Last Actual Dose of Study Drug (SVR24), Summarized by Formulation, Age and Weight Group, Across All Subjects, and Across All Subjects on the Adult Formulations

    SVR24 is defined as hepatitis C virus ribonucleic acid (HCV RNA) \< lower limit of quantification (LLOQ) 24 weeks after the last actual dose of study drug.

    Time frame: 24 weeks after last dose of study drug (Week 36 or 48 depending on treatment duration)

  3. Parts 1 and 2: Percentage of Participants With Alanine Aminotransferase (ALT) Normalization During Treatment by Formulation, Age and Weight Group, Across All Subjects, and Across All Subjects on the Adult Formulations

    Alanine aminotransferase (ALT) normalization during treatment is defined as ALT ≤ the upper limit of normal (ULN) at the final treatment visit for participants with ALT \> ULN at baseline.

    Time frame: 12 or 24 weeks after starting study drug, depending on treatment duration

07

Results

Posted Oct 5, 2021

Participant flow

Participant flow — Overall Study
MilestoneAdult Tablet, 12-17 yr, Part 1Adult Tablet, 12-17 yr, Part 2Mini Tablet, 9-11 yr, Part 1Mini Tablet, 3-8 yr, Part 1
Started12261214
Completed10231010
Not completed2324
Withdrew: Withdrew consent1001
Withdrew: Lost to follow-up1313
Withdrew: Other, not specified0010

Outcome measures

PrimaryPart 1: Maximum Plasma Concentration (Cmax) of Ombitasvir (OBV)

Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.

Time frame:
At Week 2
Reported as:
Geometric mean · ng/mL
Part 1: Maximum Plasma Concentration (Cmax) of Ombitasvir (OBV)
ng/mL15 - 29 kg Body Weight30 - 44 kg Body Weight≥ 45 kg Body Weight
Part 1: Maximum Plasma Concentration (Cmax) of Ombitasvir (OBV)99.6 ± 27116 ± 1483.7 ± 39
PrimaryPart 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Ombitasvir (OBV)

AUC is a measure of how long and how much drug is present in the body after dosing. The amount of ombitasvir present was measured up to 24 hours after dosing.

Time frame:
At Week 2
Reported as:
Geometric mean · ng•h/mL
Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Ombitasvir (OBV)
ng•h/mL15 - 29 kg Body Weight30 - 44 kg Body Weight≥ 45 kg Body Weight
Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Ombitasvir (OBV)1270 ± 261490 ± 121060 ± 43
PrimaryPart 1: Lowest Plasma Concentration (Ctrough) of Ombitasvir (OBV)

Minimum plasma concentration (Ctrough; measured in ng/mL) was directly determined from the concentration-time data.

Time frame:
At Weeks 2 and 8
Reported as:
Geometric mean · ng/mL
Part 1: Lowest Plasma Concentration (Ctrough) of Ombitasvir (OBV)
ng/mL15 - 29 kg Body Weight30 - 44 kg Body Weight≥ 45 kg Body Weight
Week 224.7 ± 3228.2 ± 1621.8 ± 39
Week 829.6 ± 7830.4 ± 2420.9 ± 58
PrimaryPart 1: Maximum Plasma Concentration (Cmax) of Paritaprevir (PTV)

Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.

Time frame:
At Week 2
Reported as:
Geometric mean · ng/mL
Part 1: Maximum Plasma Concentration (Cmax) of Paritaprevir (PTV)
ng/mL15 - 29 kg Body Weight30 - 44 kg Body Weight≥ 45 kg Body Weight
Part 1: Maximum Plasma Concentration (Cmax) of Paritaprevir (PTV)294 ± 1521540 ± 71870 ± 125
PrimaryPart 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Paritaprevir (PTV)

AUC is a measure of how long and how much drug is present in the body after dosing. The amount of paritaprevir present was measured up to 24 hours after dosing.

Time frame:
At Week 2
Reported as:
Geometric mean · ng•h/mL
Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Paritaprevir (PTV)
ng•h/mL15 - 29 kg Body Weight30 - 44 kg Body Weight≥ 45 kg Body Weight
Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Paritaprevir (PTV)2180 ± 1368640 ± 905770 ± 152
PrimaryPart 1: Lowest Plasma Concentration (Ctrough) of Paritaprevir (PTV)

Minimum plasma concentration (Ctrough; measured in ng/mL) was directly determined from the concentration-time data.

Time frame:
At Weeks 2 and 8
Reported as:
Geometric mean · ng/mL
Part 1: Lowest Plasma Concentration (Ctrough) of Paritaprevir (PTV)
ng/mL15 - 29 kg Body Weight30 - 44 kg Body Weight≥ 45 kg Body Weight
Week 29.86 ± 11316.1 ± 11218.0 ± 78
Week 817.3 ± 13618.4 ± 8923.5 ± 86
PrimaryPart 1: Maximum Plasma Concentration (Cmax) of Dasabuvir (DSV)

Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.

Time frame:
At Week 2
Reported as:
Geometric mean · ng/mL
Part 1: Maximum Plasma Concentration (Cmax) of Dasabuvir (DSV)
ng/mL15 - 29 kg Body Weight30 - 44 kg Body Weight≥ 45 kg Body Weight
Part 1: Maximum Plasma Concentration (Cmax) of Dasabuvir (DSV)579 ± 44830 ± 45671 ± 48
PrimaryPart 1: Concentration of Drug in Blood Plasma Against Time [Area Under the Curve (AUC)] of Dasabuvir (DSV)

AUC is a measure of how long and how much drug is present in the body after dosing. The amount of dasabuvir present was measured up to 12 hours after dosing. For two subjects in the 15-29 kg group, the 24 h concentration was used as the 12 h concentration due to the significant sampling time deviation. For one subject in the 30-44 kg group, the 24 h concentration was used as the 12 h concentration due to the significant sampling time deviation.

Time frame:
At Week 2
Reported as:
Geometric mean · ng•h/mL
Part 1: Concentration of Drug in Blood Plasma Against Time [Area Under the Curve (AUC)] of Dasabuvir (DSV)
ng•h/mL15 - 29 kg Body Weight30 - 44 kg Body Weight≥ 45 kg Body Weight
Part 1: Concentration of Drug in Blood Plasma Against Time [Area Under the Curve (AUC)] of Dasabuvir (DSV)3960 ± 445960 ± 474630 ± 49
PrimaryPart 1: Lowest Plasma Concentration (Ctrough) of Dasabuvir (DSV)

Minimum plasma concentration (Ctrough; measured in ng/mL) was directly determined from the concentration-time data.

Time frame:
At Weeks 2 and 8
Reported as:
Geometric mean · ng/mL
Part 1: Lowest Plasma Concentration (Ctrough) of Dasabuvir (DSV)
ng/mL15 - 29 kg Body Weight30 - 44 kg Body Weight≥ 45 kg Body Weight
Week 2110 ± 57215 ± 54165 ± 56
Week 8168 ± 82264 ± 65191 ± 60
PrimaryPart 1: Maximum Plasma Concentration (Cmax) of Ritonavir (RTV)

Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.

Time frame:
At Week 2
Reported as:
Geometric mean · ng/mL
Part 1: Maximum Plasma Concentration (Cmax) of Ritonavir (RTV)
ng/mL15 - 29 kg Body Weight30 - 44 kg Body Weight≥ 45 kg Body Weight
Part 1: Maximum Plasma Concentration (Cmax) of Ritonavir (RTV)1090 ± 671830 ± 421180 ± 35
PrimaryPart 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Ritonavir (RTV)

AUC is a measure of how long and how much drug is present in the body after dosing. The amount of ritonavir present was measured up to 24 hours after dosing.

Time frame:
At Week 2
Reported as:
Geometric mean · ng•h/mL
Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Ritonavir (RTV)
ng•h/mL15 - 29 kg Body Weight30 - 44 kg Body Weight≥ 45 kg Body Weight
Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Ritonavir (RTV)6570 ± 6014100 ± 498900 ± 37
PrimaryPart 1: Lowest Plasma Concentration (Ctrough) of Ritonavir (RTV)

Minimum plasma concentration (Ctrough; measured in ng/mL) was directly determined from the concentration-time data.

Time frame:
At Weeks 2 and 8
Reported as:
Geometric mean · ng/mL
Part 1: Lowest Plasma Concentration (Ctrough) of Ritonavir (RTV)
ng/mL15 - 29 kg Body Weight30 - 44 kg Body Weight≥ 45 kg Body Weight
Week 216.1 ± 7232.1 ± 6329.8 ± 54
Week 891.8 ± 26838.1 ± 11258.2 ± 138
PrimaryParts 1 and 2: Percentage of Participants With Sustained Virologic Response 12 Weeks After the Last Actual Dose of Study Drug (SVR12)

SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) \< lower limit of quantification (LLOQ) 12 weeks after the last actual dose of study drug.

Time frame:
12 weeks after last dose of study drug (Week 24 or 36 depending on treatment duration)
Reported as:
Number · percentage of participants
Parts 1 and 2: Percentage of Participants With Sustained Virologic Response 12 Weeks After the Last Actual Dose of Study Drug (SVR12)
percentage of participantsAll Participants, Total
Parts 1 and 2: Percentage of Participants With Sustained Virologic Response 12 Weeks After the Last Actual Dose of Study Drug (SVR12)98.4 (91.7 to 99.7)
Statistical analysis
  • All Participants, Total · Wilson's score method: 98.4 · 95% CI 91.7 to 99.7
SecondaryParts 1 and 2: Percentage of Participants With Sustained Virologic Response 12 Weeks After the Last Actual Dose of Study Drug (SVR12) Summarized by Formulation, Age and Weight Group, and Across All Subjects on the Adult Formulations

SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) \< lower limit of quantification (LLOQ) 12 weeks after the last actual dose of study drug.

Time frame:
12 weeks after last dose of study drug (Week 24 or 36 depending on treatment duration)
Reported as:
Number · percentage of participants
Parts 1 and 2: Percentage of Participants With Sustained Virologic Response 12 Weeks After the Last Actual Dose of Study Drug (SVR12) Summarized by Formulation, Age and Weight Group, and Across All Subjects on the Adult Formulations
percentage of participantsAdult Tablet, 12-17 YR, ≥ 45 kgMini-tablet, 9-11 YR, 15 to 29 kgMini-tablet, 9-11 YR, 30 to 44 kgMini-tablet, 9-11 YR, ≥ 45 kgMini-tablet, 3-8 YR, 15 to 29 kgMini-tablet Total
Parts 1 and 2: Percentage of Participants With Sustained Virologic Response 12 Weeks After the Last Actual Dose of Study Drug (SVR12) Summarized by Formulation, Age and Weight Group, and Across All Subjects on the Adult Formulations100 (90.8 to 100.0)100 (20.7 to 100.0)100 (70.1 to 100.0)100 (34.2 to 100.0)92.9 (68.5 to 98.7)96.2 (81.1 to 99.3)
SecondaryParts 1 & 2: Percentage of Participants With Sustained Virologic Response 24 Weeks After the Last Actual Dose of Study Drug (SVR24), Summarized by Formulation, Age and Weight Group, Across All Subjects, and Across All Subjects on the Adult Formulations

SVR24 is defined as hepatitis C virus ribonucleic acid (HCV RNA) \< lower limit of quantification (LLOQ) 24 weeks after the last actual dose of study drug.

Time frame:
24 weeks after last dose of study drug (Week 36 or 48 depending on treatment duration)
Reported as:
Number · percentage of participants
Parts 1 & 2: Percentage of Participants With Sustained Virologic Response 24 Weeks After the Last Actual Dose of Study Drug (SVR24), Summarized by Formulation, Age and Weight Group, Across All Subjects, and Across All Subjects on the Adult Formulations
percentage of participantsParticipants in Parts 1 and 2 of the StudyAdult Tablet, 12-17 YR, ≥ 45 kgMini-tablet, 9-11 YR, 15 to 29 kgMini-tablet, 9-11 YR, 30 to 44 kgMini-tablet, 9-11 YR, ≥ 45 kgMini-tablet, 3-8 YR, 15 to 29 kgMini-tablet Total
Parts 1 & 2: Percentage of Participants With Sustained Virologic Response 24 Weeks After the Last Actual Dose of Study Drug (SVR24), Summarized by Formulation, Age and Weight Group, Across All Subjects, and Across All Subjects on the Adult Formulations96.9 (89.3 to 99.1)100 (90.8 to 100.0)100.0 (20.7 to 100.0)88.9 (56.5 to 98.0)100.0 (34.2 to 100.0)92.9 (68.5 to 98.7)92.3 (75.9 to 97.9)
SecondaryParts 1 and 2: Percentage of Participants With Alanine Aminotransferase (ALT) Normalization During Treatment by Formulation, Age and Weight Group, Across All Subjects, and Across All Subjects on the Adult Formulations

Alanine aminotransferase (ALT) normalization during treatment is defined as ALT ≤ the upper limit of normal (ULN) at the final treatment visit for participants with ALT \> ULN at baseline.

Time frame:
12 or 24 weeks after starting study drug, depending on treatment duration
Reported as:
Number · percentage of participants
Parts 1 and 2: Percentage of Participants With Alanine Aminotransferase (ALT) Normalization During Treatment by Formulation, Age and Weight Group, Across All Subjects, and Across All Subjects on the Adult Formulations
percentage of participantsAdult Tablet,12-17 YR, ≥ 45 kg, ALT NormalizationMini-tablet, 9-11 YR, 15 to 29 kg, ALT NormalizationMini-tablet, 9-11 YR, 30 to 44 kg, ALT NormalizationMini-tablet, 3-8 YR, 15 to 29 kg, ALT NormalizationMini-tablet Total, ALT NormalizationParticipants in Parts 1 and 2 of the Study, ALT Normalization
Parts 1 and 2: Percentage of Participants With Alanine Aminotransferase (ALT) Normalization During Treatment by Formulation, Age and Weight Group, Across All Subjects, and Across All Subjects on the Adult Formulations87.5 (69.0 to 95.7)100 (20.7 to 100.0)100 (56.6 to 100.0)80.0 (49.0 to 94.3)87.5 (64.0 to 96.5)87.5 (73.9 to 94.5)

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the first dose of study drug until 30 days after last dose, up to 37 weeks. SAEs and protocol-related nonserious AEs were collected from the time the subject signed consent.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adult Tablet, 12-17 yr, Part 10/12 (0%)0/12 (0%)11/12 (91.7%)
Adult Tablet, 12-17 yr, Part 20/26 (0%)0/26 (0%)17/26 (65.4%)
Adult Tablet, 12-17 yr, Total0/38 (0%)0/38 (0%)28/38 (73.7%)
Mini Tablet, 9-11 yr, Part 10/12 (0%)1/12 (8.3%)12/12 (100%)
Mini Tablet, 3-8 yr, Part 10/14 (0%)0/14 (0%)9/14 (64.3%)
Mini Tablet, Total0/26 (0%)1/26 (3.8%)21/26 (80.8%)
All Participants, Total0/64 (0%)1/64 (1.6%)49/64 (76.6%)
Most frequent serious events
Most frequent serious events
EventAdult Tablet, 12-17 yr, Part 1Adult Tablet, 12-17 yr, Part 2Adult Tablet, 12-17 yr, TotalMini Tablet, 9-11 yr, Part 1Mini Tablet, 3-8 yr, Part 1Mini Tablet, TotalAll Participants, Total
LeukopeniaBlood and lymphatic system disorders0/120/260/381/120/141/261/64
NeutropeniaBlood and lymphatic system disorders0/120/260/381/120/141/261/64
Most frequent other events
Showing 10 of 77
Most frequent other events
EventAdult Tablet, 12-17 yr, Part 1Adult Tablet, 12-17 yr, Part 2Adult Tablet, 12-17 yr, TotalMini Tablet, 9-11 yr, Part 1Mini Tablet, 3-8 yr, Part 1Mini Tablet, TotalAll Participants, Total
FatigueGeneral disorders2/125/267/385/121/146/2613/64
HeadacheNervous system disorders3/125/268/385/122/147/2615/64
VomitingGastrointestinal disorders0/121/261/384/121/145/266/64
DiarrhoeaGastrointestinal disorders0/121/261/383/120/143/264/64
NauseaGastrointestinal disorders3/120/263/383/121/144/267/64
PyrexiaGeneral disorders2/121/263/383/122/145/268/64
Upper respiratory tract infectionInfections and infestations2/122/264/381/123/144/268/64
Abdominal painGastrointestinal disorders2/120/262/381/120/141/263/64
Abdominal pain upperGastrointestinal disorders0/121/261/382/120/142/263/64
FlatulenceGastrointestinal disorders0/120/260/382/120/142/262/64

Baseline characteristics

Intention-to-treat population: all participants who received at least one dose of study drug in Part 1 or Part 2

Age, Continuous
Age, Continuous(years)Adult Tablet, 12-17 yr, Part 1Adult Tablet, 12-17 yr, Part 2Mini Tablet, 9-11 yr, Part 1Mini Tablet, 3-8 yr, Part 1Total
Mean15.4 ± 1.7315.0 ± 1.689.8 ± 0.834.8 ± 1.6711.9 ± 4.54
Sex: Female, Male
Sex: Female, Male(Participants)Adult Tablet, 12-17 yr, Part 1Adult Tablet, 12-17 yr, Part 2Mini Tablet, 9-11 yr, Part 1Mini Tablet, 3-8 yr, Part 1Total
Female91661142
Male3106322
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Adult Tablet, 12-17 yr, Part 1Adult Tablet, 12-17 yr, Part 2Mini Tablet, 9-11 yr, Part 1Mini Tablet, 3-8 yr, Part 1Total
White623101049
Black or African American23049
Asian30104
American Indian or Alaska Native00000
Native Hawaiian or Other Pacific Islander00000
Multi race10102
08

Study locations

21 sites
  • UCSF Benioff Childrens Hosp /ID# 136774
    San Francisco, California 94158, United States
  • Children's Hospital Colorado /ID# 137017
    Aurora, Colorado 80045, United States
  • University of Florida - Archer /ID# 136830
    Gainesville, Florida 32610, United States
  • Advent Health /ID# 167663
    Orlando, Florida 32803, United States
  • Indiana University /ID# 137015
    Indianapolis, Indiana 46202, United States
  • Boston Childrens Hospital /ID# 137174
    Boston, Massachusetts 02115, United States
  • Boston Medical Center /ID# 136831
    Boston, Massachusetts 02118, United States
  • Columbia Univ Medical Center /ID# 136431
    New York, New York 10032-3725, United States
  • Children's Hospital of Philadelphia /ID# 137018
    Philadelphia, Pennsylvania 19104, United States
  • Baylor College of Medicine /ID# 136590
    Houston, Texas 77030-3411, United States
  • Seattle Children's Hospital /ID# 137019
    Seattle, Washington 98105, United States
  • Cliniques Universitaires Saint-Luc /ID# 136910
    Brussels, Bruxelles-Capitale 1200, Belgium
  • UZ Leuven /ID# 136911
    Leuven, 3000, Belgium
  • Charite Universitaetsmedizin Berlin /ID# 141620
    Berlin, 10117, Germany
  • Universitaetsklinikum Freiburg /ID# 141618
    Freiburg, 79106, Germany
  • Helios Klinikum Wuppertal /ID# 142883
    Wuppertal, 42283, Germany
  • San Jorge Children Hospital /ID# 136832
    San Juan, 00912-3310, Puerto Rico
  • Hospital Sant Joan de Deu /ID# 137096
    Esplugues de Llobregat, Barcelona 08950, Spain
  • Hospital Universitario Vall d'Hebron /ID# 137098
    Barcelona, 08035, Spain
  • Hospital Universitario La Paz /ID# 137094
    Madrid, 28046, Spain
  • Hospital Universitario y Politecnico La Fe /ID# 137097
    Valencia, 46026, Spain
09

References and documents

Publications

  • Rosenthal P, Narkewicz MR, Yao BB, Jolley CD, Lobritto SJ, Wen J, Molleston JP, Hsu EK, Jonas MM, Zha J, Liu L, Leung DH. Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a. Adv Ther. 2020 Jul;37(7):3299-3310. doi: 10.1007/s12325-020-01389-9. Epub 2020 May 25. PubMed 32451952 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Nov 2020, 60 months.

Results were first posted in Oct 2021, 10 months after primary completion.

Of 14 phase 2/3 interventional studies under Hepatitis C, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 51. This study's 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2015
First posted
Jul 1, 2015
StartActual
Oct 28, 2015
Primary completionActual
Nov 19, 2020
CompletionActual
Nov 19, 2020
Results first posted
Oct 5, 2021
Last update
Oct 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02486406
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 1, 2015
Start date
Oct 28, 2015
Primary completion
Nov 19, 2020
Completion
Nov 19, 2020
Results posted
Oct 5, 2021
Last update
Oct 5, 2021

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ombitasvir/Paritaprevir/Ritonavir · Ribavirin

Start the discussion